Impact Factor
4.12
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
6.42
1,401 total citations
h5-index
44
h5 depth signal
Cited share
78.5%
186 of 237
Total citations
1,401
Citation footprint
Metric signal
7.03
External metric anchor
Self-citation
6.1%
85 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
491
United Kingdom
304
Netherlands
196
France
148
Italy
128
Citing Fields of Research
Medical Ethics
539
Pharmacology & Toxicology
487
Patient Care
287
Cardiology
98
AI & Machine Learning
92
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
4,253
Articles tracked across the journal lifetime
Indexed publication set
237
186 cited publications
Last 12 months
108
9.0 publications/month
Open access share
59.3%
64 OA publications in the last year
Leading citing country
United States
491 citing publications
Leading citing field
Medical Ethics
539 citing publications
Latest tracked publication
14 October 2026
10 recent records available
Coverage & Indexing History
v5n1, Jan./Feb. 1990-
v5n1, Jan./Feb. 1990-
Active Coverage
Research Focus & Classification
Indexed Subjects
Medical Ethics
Pharmacology & Toxicology
Patient Care
Obstetrics/Gynecology
AI & Machine Learning
Broad Categories
Drug Therapy
Toxicology
Medical Ethics
MeSH Descriptors
Drug-Related Side Effects and Adverse Reactions
Toxicology
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1007/s40264-026-01734-x
Open DOI
Current Pharmacovigilance Outsourcing Practices in Arab Countries
02
03
04
05
DOI 10.1007/s40264-026-01735-w
Open DOI
Hierarchical Algorithms for Constructing Mother–Father–Infant Linkages Under Modern Privacy Constraints
06
07
08
DOI 10.1007/s40264-026-01712-3
Open DOI
Drug Brand Switching: A Regulatory Perspective
09
10
DOI 10.1007/s40264-026-01731-0
Open DOI
Signal Detection of Adverse Events Associated with PCSK9 Inhibitors: A Nationwide Sequence Symmetry and Combined Worldwide Disproportionality Analysis
Background and Aim Despite the increasing use of proprotein convertase subtilisin/kexin type 9-inhibitors (PCSK9i), their safety assessment from large real-world databases remains limited. We aimed to perform a large-scale safety signals...
Bibliographical & Catalog Notes
Title from cover.
Subtitle: an international journal of medical toxicology and drug experience.
Also issued online.